The MEDD myth: the impact of pseudoscience on pain research and prescribing-guideline development

Jeffrey Fudin
Jacqueline Pratt Cleary
Michael E Schatman

1Western New England University College of Pharmacy, Springfield, MA, 2Stratton VA Medical Center, Albany, NY, 3US Pain Foundation, Bellevue, WA, USA

With the opioid-misuse and -abuse problem on the rise, pain practitioners and lawmakers are scrambling for strategies to help mitigate opioid risks. Approaches include opioid-treatment agreements, urine drug testing, prescription-monitoring programs, assorted validated risk-assessment tools for abuse/misuse and opioid-induced respiratory depression (OIRD), biopsychosocial support, and other strategies.1–3 Nonopioid pain therapies should be considered and maximized prior to initiating opioid treatment; however, in some cases opioids are the optimal choice for both noncancer and cancer-related pain syndromes.4

Aside from these strategies to curtail a number of opioid-associated risks, the professional literature ubiquitously employs morphine-equivalent daily dose (MEDD) and other comparable acronyms to attribute escalating risks based on overall daily opioid dose.1,4,5 One maneuver that is frequently endorsed to avert OIRD is daily opioid-dose reduction measured by MEDD.6–8 Since potency, receptor-binding affinity, physical tolerance, and various pharmacokinetic attributes differ among opioids, the concept of MEDD was employed to justify transitioning from a currently prescribed opioid to one or more opioid “equivalents”.9 However, the defined daily dosage (DDD) of one opioid does not necessarily exhibit the same effects of the DDD of another opioid. This distinction then creates a problem clinically when opioid consumption is being considered. Svedsen et al,9 for example, conducted an analysis comparing DDD and oral morphine equivalent (OMEQ). It should be noted, however, that due to the variations in equivalence calculators and numerous sources having different potency-equivalent estimators, there were several identified limitations to the concept of OMEQ. The authors excluded methadone altogether, due to conversion issues. Nevertheless, methadone is included precipitously throughout the literature as part of MEDD, and has also been attributed to an elevated risk level aside from its calculated MEDD.9 Svedsen et al determined that the range of equianalgesic ratios varies dramatically between certain opioids.9 For example, when converted to morphine equivalents, fentanyl’s conversion ranged from 68 to 150 mg, and buprenorphine ranged from 33.3 to 60 mg. The authors demonstrated several of the concerns with variations in using OMEQ, and raised the question of why OMEQ is even the standard conversion cited by the medical literature and clinicians.

Considering the plethora of literature that relies on MEDD to assign opioid and public health risks, as well as to study various opioid-prescribing trends, we question
that utilization of various dosage-conversion tablets and methadone of ±166 mg MEDD. This study illustrated that utilization of various dosage-conversion tablets and equianalgesic ratios that have been published could lead to dramatic underdosing or fatal overdosing in some cases. In 2014, Shaw and Fudin conducted a survey comparing various online opioid dose-conversion tools and found a −55% to +242% variation across eight opioid-conversion calculators. The standard deviations in these two studies alone exceeded many of the MEDD maximums that several states have employed to trigger consultation from a certified pain expert. These studies alone unequivocally disqualify the validity of embracing MEDD to assess risk in any meaningful statistical way. Outside of MEDD calculations, there are several factors that also require consideration, but that remain largely ignored. These include patient-specific attributes, such as pharmacogenetics, organ dysfunction, overall pain control, drug tolerance, drug–drug interactions, drug–food interactions, patient age, and body surface area. The bottom line is that as the scientific concepts upon which prescribing guideline authors depend are flawed and invalid, so are the guidelines themselves. As a result, we posit that these guidelines are disingenuous and highly unethical.

Opiate overdoses unfortunately can occur at any dose, and patients are at risk on even low-dose opioids. Zedler et al developed a risk index for OIRD in the veteran population. This validated risk tool illustrated that in veteran populations, even a daily morphine equivalence of 20 mg/day equates to an increase in OIRD. Greater risk of OIRD is associated with higher daily morphine equivalence; however, Dasgupta et al concluded that dose-dependent opioid-overdose risk among patients did not have a distinct risk threshold.

While Zedler et al’s validated multivariate linear regression model for OIRD clearly established elevated risks for patients with comorbid psychiatric illness, end-organ dysfunction, and more, these items are inherently ignored when establishing state and national guidelines that habitually rely only upon MEDD. These important comorbid liabilities considered in the Risk Index for Serious Prescription Opioid-Induced Respiratory Depression or Overdose (RIOSORD) are important parameters that unjustifiably have lacked consideration. Moreover, if we do rely on drug therapy alone, it is clear that the majority of opioid-related deaths are attributable to a combination of opioids plus sedative hypnotics and/or alcohol. If we accept this as fact, assigned risks should be based on an opioid:sedative hypnotic ratio rather than opioids alone. The difficulty here is that elevated risks associated with sedating drugs, such as alcohol, benzodiazepines, imidazopridines, pyrazolopyrimidines, cyclopyrrolones, various other skeletal muscle relaxants, such as carisoprodol and meprobamate, antidepressants, antipsychotics, anticonvul-
sants, antihistamines, and many others, have unique inherent risks as single agents. However, while many of these agents are ordinarily prescribed concomitantly, minimal attention has been attributed to their combined risks, most probably because of this unpredictability.

As a final point, we believe that it is important to address the continued utilization of MEDD as a dependent variable in pain research. A PubMed search of recent publications indicates the continued use of this archaic concept in studies of both cancer and noncancer pain. Unlike the zealots who are heavily responsible for recent opioid-prescribing guidelines and trends, we do not necessarily believe that researchers who continue to rely upon the concept of MEDD are being disingenuously agenda-driven in doing so. Rather, researchers’ use of MEDD continues to be commonplace, simply because doing so has been conveniently accepted rather than methodically questioned. It is easier to ignore pharmacogenomics and individualized therapy, and “jump” all opioids and patients together based on the denominator of MEDD, as opposed to comparing the impact of an intervention on individual consumption of opioids, such as morphine, fentanyl, and methadone. However, just as prescribing guidelines are based on flawed formulas and evidence, invalid concepts can make research invalid. We are thus compelled to consider whether outcome research that continues to rely upon the concept of MEDD is also invalidated by such. Our hope as researchers is that our colleagues will acknowledge this imbroglio and convert their processes of outcome research in a manner that will produce more valid and meaningful results for individual patients, rather than meaningless cohorts.

Single-dose studies, expert opinion, and observations are largely the source from which equianalgesic tables are derived. With the exception of methadone conversions, published studies have been conducted in noncancer patients and have not accounted for inter- and intrapatient variability. Based on the marked variability of dosing conversions from one opioid to another, the lack of a distinct risk threshold, and various patient variabilities, the concepts of MEDD and daily limits are grossly flawed. How any agency, clinician, or lawmaker can claim a daily limit on total morphine equivalence and/or dispensed dosage units is mind-boggling when there is obviously no accurate, validated, or universally accepted way to calculate total MEDD. Tragically, this is what the United States Centers for Disease Control and Prevention (CDC) Guideline for Prescribing Opioids for Chronic Pain has done. Simply put, it is scientifically, ethically, and morally inexplicable. Therefore, the flawed concept of MEDD should not necessarily be used to guide clinicians when adjusting opioid doses or rotating from one to another. In our opinion, impressionist lawmakers and antiopioid zealots are basing clinical policy decisions on flawed concepts that ultimately could adversely affect positive outcomes for legitimate pain patients. Let us hope that pain researchers will lead the way in developing a much-needed and ethical paradigmatic revision, as the MEDD myth must be dispelled.

Disclosure

JF reports the following: Astra Zeneca (speakers bureau, advisory board); DepoMed (advisory board); Endo (consultant); Kaléo (speakers bureau, advisory board); KemPharm (consultant); Millennium Health LLC (speakers bureau, advisory board, expert witness); Practical Pain Management (development of online opioid-conversion calculator); Remitigate LLC (founder, owner); Scilex Pharmaceuticals (consultant); and Zogenix (consultant). The other authors report no conflicts of interest. This editorial represents the opinions of the authors, and has not been reviewed or prepared as part of any government agency or companies listed.

References


